Kymera Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	1,854	1,413	1,369	3,263	2,756	-	Upgrade
Market Cap Growth	50.25%	3.16%	-58.03%	18.36%	-	-	Upgrade
Enterprise Value	1,415	1,117	973	2,832	2,477	-73	Upgrade
PE Ratio	-	-9.61	-8.85	-32.55	-50.44	-	Upgrade
PS Ratio	23.35	17.98	29.25	44.80	80.99	-	Upgrade
PB Ratio	2.61	3.58	2.79	7.10	9.71	-	Upgrade
P/FCF Ratio	-18.02	-10.29	-8.78	-24.99	34.88	-	Upgrade
P/OCF Ratio	-24.95	-13.74	-8.95	-25.30	31.28	-	Upgrade
EV/Sales Ratio	17.82	14.21	20.79	38.88	72.77	-24.72	Upgrade
EV/EBITDA Ratio	-13.43	-7.80	-6.42	-29.00	-56.65	1.80	Upgrade
EV/EBIT Ratio	-13.07	-7.61	-6.30	-28.31	-54.46	1.76	Upgrade
EV/FCF Ratio	-14.80	-8.13	-6.24	-21.69	31.34	-4.18	Upgrade
Debt / Equity Ratio	0.12	0.21	0.04	0.04	0.06	-0.28	Upgrade
Debt / EBITDA Ratio	-0.58	-0.59	-0.11	-0.18	-0.41	-0.52	Upgrade
Debt / FCF Ratio	-0.64	-0.62	-0.11	-0.14	0.23	1.22	Upgrade
Quick Ratio	9.38	4.62	5.79	4.85	2.70	2.71	Upgrade
Current Ratio	9.57	4.73	5.88	4.88	2.73	2.69	Upgrade
Asset Turnover	0.12	0.14	0.08	0.14	0.11	0.04	Upgrade
Interest Coverage	-735.15	-748.81	-878.59	-571.67	-395.46	-895.65	Upgrade
Return on Equity (ROE)	-31.90%	-34.80%	-33.80%	-27.20%	-52.20%	75.80%	Upgrade
Return on Assets (ROA)	-24.00%	-25.30%	-26.60%	-18.70%	-18.10%	-51.30%	Upgrade
Return on Capital (ROIC)	-22.30%	-34.51%	-31.78%	-21.05%	-15.34%	79.31%	Upgrade
Earnings Yield	-8.34%	-10.40%	-11.30%	-3.07%	-1.98%	-	Upgrade
FCF Yield	-7.35%	-9.72%	-11.39%	-4.00%	2.87%	-	Upgrade
Buyback Yield / Dilution	-21.63%	-8.22%	-12.39%	-176.60%	-921.45%	9.44%	Upgrade
Total Shareholder Return	-21.63%	-8.22%	-12.39%	-176.60%	-921.45%	9.44%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).